# MMR-MSI testing in practice: a single tertiary centre study



Joy Staniforth; Yuanxue Huang, PhD; Hongxiang Liu, PhD; Olivier Giger, MD, PhD

### **Introduction & Methods**

Cambridge

University Hospitals NHS Foundation Trust

# Lynch syndrome (LS) is a hereditary condition associated with a high risk for colorectal cancer (CRC)

 LS is caused by germline mutations in DNA mismatch repair (MMR) genes. Incidence 2-4% all CRC

## Deficient DNA MMR can be seen in Lynch syndrome, however can be also seen in sporadic CRC

- The BRAF V600E mutation is associated with MHL1 promoter hypermethylation
- Sequential BRAF V600E and MLH1 promoter hypermethylation testing differentiates sporadic and LS-associated CRC

# The two screening tests used in the prediction of LS are MMR protein expression assessed by immunohistochemistry (IHC) and DNA microsatellite instability (MSI) analysis


- Previously accepted knowledge had been that MSI was superior to IHC in predicting a germline mutation
- However, later studies showed that, whilst both methods had their
- limitations, MSI was more sensitive than IHC but slightly less specific To ascertain the presence and level of discrepancy between the two

methods, we compared our IHC and MSI results retrospectively

#### Patient selection:

- Preselected CRC cases (<50 years or histomorphological / family history criteria suggestive of LS)</li>
- Where MMR IHC testing was performed between March 2013 and March 2017

#### Techniques: MSI: Promega MSI Analysis System; BRAF: V600E mutation




## **Results: Identified MMR-MSI Discrepancies**

Case	MLH1	PMS2	MSH2	MSH6	Comment
1*	+	+	+	+	No germline mutation in any of the four genes
2	+	-	+	+	All IHC originally reported as positive. Germline mutation in MLH1
3	+	+	+	-/-	All IHC originally reported as positive.
					Germline mutation in MSH6

#### Case 1





	usions
Golig	

#### Discrepancies between MMR and MSI are rare (2/379 (0.5%))

- Performing either test alone may result in patients warranting further investigation for germline mutations being missed
- This has additional importance in view of recent FDA approval of pembrolizumab for MSI-H/MMR-deficient solid tumours
- Is there a need for MMR IHC guidance for pathologists in view of the difficulties of interpretation?

#### Testing on aged FFPE samples can be problematic

- Limitations in PCR success related to poor DNA quality
- Though aged specimens often show retained MMR IHC, IHC performance can also be affected by prolonged storage
- Failure of successful MSI testing especially on aged specimens should therefore result in routine genetic discussion regardless of MMR IHC status.

## **Results: Summary Table**

		MSI not done: <b>65</b> (15% of MMR proficient;13% of total cases)				
Total cases: <b>516</b>			MS stable: 333/354 (94%)			
	MMR	MSI done: 354 (84% of MMR proficient; 68% of total cases)	Likely / suboptimal MSS: 8/354 (2.3%)			
	proficient: 419 (81%)		MSI-high: 3/354 (0.8%)			
			MSI-indeterminate: 2/354 (0.6%) One case indeterminate due to technical failure			
			Sample unsuitable: 8/354 (2.3%) 6 specimens were aged 11-29yrs			
		MSI not done: <b>72</b> (74% of MMR deficient 14% of total cases) MLH1 and or PMS2 abnormal: 60/72 (83%) • BRAF V600E mutation 29/50 (58%)				
			MS stable: 4/25 (16%)			
	MMR deficient: <b>97</b> (19%)		(4% of MMR deficient; 0.8% total) MLH1 and or PMS2 abnormal: 4/4 (100%) 6			
		MSI done: 25 (26% of MMR deficient; 5% of total cases)	BRAF V600E mutation 0/1 (0%) 7			
			Likely MSI-high: 1/25 (4%) 23yrs of storage caused suboptimal DNA quality			
			MSI-high: 20/25 (80%) MLH1 and or PMS2 abnormal: 14/20 (70%) • BRAF V600E mutation 3/8 (38%)			

Case	MLH1	PMS2	MSH2	MSH6	Comment
4	+ (weak)	+ (weak)	+/+	+	PMS2 originally reported as negative, no MLH1 germline or loss of heterozygosity (LOH)
5 *	-/+/-	-/-/-	+/+/+	-/-/-	No MLH1 germline or LOH
6	+/+	+/+	+	+	Original report states "Interpretation of MLH1 and PMS2 is difficult with focal weak nuclear positivity". BRAF mutation negative
7	+	+	+	+	MLH1/PMS2 originally reported as weak. BRAF not done



UNIVERSITY OF CAMBRIDGE